Cyclopharm Secures Three-Year Deal With University of Pennsylvania Health System
MT Newswires Live
Mar 23
Cyclopharm (ASX:CYC) secured an agreement with the University of Pennsylvania Health System (UPHS) for its Technegas technology, covering 11 clinical locations across Pennsylvania and New Jersey for an initial three-year term, according to a Monday filing with the Australian bourse.
The agreement provides for two Technegas installations at the Hospital of the University of Pennsylvania and at the Perelman Center for Advanced Medicine, as well as contracted installations across a further nine sites in the UPHS network over time, the filing said.
The agreement also allows for the potential of expanding beyond the initially contracted 11 locations to additional sites affiliated with UPHS, per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.